Holger Diedrichs*1, Ulrike Wollenberg2, Kristin Schmerbach2, Roger Limberg2, Guido Schiffhorst3, Andreas Michael Zeiher4 1Herzzentrum, Uniklinik Köln, Kerpener Straße 62, 50937, Cologne, Germany 2Berlin-Chemie AG, Glienicker Weg 125, 124 Berlin, Berlin, Germany 3IGES Institut GmbH, Friedrichstraße 180, 10117 Berlin, Berlin, Germany 4Klinikum der Johann-Wolfgang Goethe-Universität, Medizinische ...

Among implantable cardioverter-defibrillator (ICD) recipients, there are patients with recurrent episodes of electrical storm (ES), retractable to the optimal antiarrhythmic drug therapy or invasive ablation procedures. A relatively novel anti-ischemic drug with also antiarrhythmic properties, ranolazine, may effectively suppress ventricular arrhythmias in such patients for a long period of time.

AIMS The mechanistic basis of the symptoms and signs of myocardial ischaemia in patients without obstructive coronary artery disease (CAD) and evidence of coronary microvascular dysfunction (CMD) is unclear. The aim of this study was to mechanistically test short-term late sodium current inhibition (ranolazine) in such subjects on angina, myocardial perfusion reserve index, and diastolic fillin...

102 www.thelancet.com Vol 387 January 9, 2016 to be clinically signifi cant, and about 25% because PCI was likely to cause complications, would have a low likelihood of success, or failed. It is plausible that the eff ect of ranolazine might vary according to the reasons for incomplete revascularisation. Residual ischaemia caused by these untreated lesions is likely to be less in patients in wh...

Diastolic depolarization (DD) of atrial myocytes can lead to spontaneous action potentials (APs) and, potentially, atrial tachyarrhythmias. This study examined the hypotheses that 1) a slowly inactivating component of the Na(+) current (referred to as late I(Na)) may contribute to DD and initiate AP firing and that 2) blocking late I(Na) will reduce spontaneous and induced firing of APs by atri...

HPLC method has been developed for determination of Ranolazine together with its related substances in a laboratory mixture for drug and excipient compatibility studies as well as in a novel extended release tablet developed in-house. Efficient chromatographic separation was achieved on a Supelcosil C 18, (250×4.6 mm, 5 μm) column with mobile phase containing combination of Phosphate buffer pH ...

Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets A multi-scale investigation of repolarization variability and its role in cardiac arrhythmogenesis Novel blockers of hyperpolarization-activated current with isoform...